富血小板血浆对女性雄激素性脱发的影响：一项随机对照试验。

The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial.

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

J Am Acad Dermatol. 2020 Nov;83(5):1294-1297. doi: 10.1016/j.jaad.2020.06.1021. Epub 2020 Jul 7.

DOI:10.1016/j.jaad.2020.06.1021

PMID:32649961

Abstract

BACKGROUND

Platelet-rich plasma (PRP) may be a useful treatment for androgenetic alopecia (AGA), although objective studies are needed.

OBJECTIVE

To determine whether PRP injections improve female AGA.

METHOD

Prospective randomized controlled trial of 30 women diagnosed with AGA. Patients received subdermal scalp injections of Eclipse system PRP or placebo saline at weeks 0, 4, and 8. Outcome measures were changes in hair density (hair/cm), hair caliber (mm), and blinded global photographic assessment (improved or not improved) at week 24.

RESULTS

Blinded global photographic assessment indicated that 57% of patients receiving PRP versus 7% of patients receiving saline improved at week 24 from baseline (P < .01). Compared to baseline, there was improvement in mean density in the PRP group versus the placebo group at week 8 (+71.1 vs -26.7 hairs/cm; P < .01) and week 24 (+105.9 vs -52.4 hairs/cm; P < .01). Compared to baseline, there was improvement in mean caliber in the PRP group versus the placebo group at week 8 (+0.0043 vs -0.0034 mm; P < .01) and week 24 (+0.0053 vs -0.0060 mm; P < .01). Adverse effects included headache, scalp tightness, swelling, redness, and postinjection bleeding.

LIMITATIONS

Two patients lost to follow-up.

CONCLUSIONS

PRP with the Eclipse system is a safe and effective intervention for female AGA.

摘要

背景

富含血小板的血浆（PRP）可能是治疗雄激素性脱发（AGA）的有效方法，但需要进行客观研究。

目的

确定 PRP 注射是否改善女性 AGA。

方法

对 30 名被诊断为 AGA 的女性进行前瞻性随机对照试验。患者在第 0、4 和 8 周接受 Eclipse 系统 PRP 或安慰剂生理盐水的皮下头皮注射。在第 24 周，通过头发密度（每平方厘米的头发数）、头发直径（毫米）和盲法整体照片评估（改善或未改善）来评估结果。

结果

盲法整体照片评估表明，接受 PRP 的患者中有 57%在第 24 周时从基线改善，而接受生理盐水的患者仅有 7%（P<.01）。与基线相比，PRP 组在第 8 周和第 24 周时的平均密度均有改善（PRP 组+71.1 比-26.7 根/平方厘米；P<.01）和第 24 周（PRP 组+105.9 比-52.4 根/平方厘米；P<.01）。与基线相比，PRP 组在第 8 周和第 24 周时的平均直径也有所改善（PRP 组+0.0043 比-0.0034 毫米；P<.01）和第 24 周（PRP 组+0.0053 比-0.0060 毫米；P<.01）。不良反应包括头痛、头皮紧绷、肿胀、发红和注射后出血。